Skip to content
Credit reportVerdict and grounds
Made on 20-11-2026 at 13:58
Reference CK-1013386219-20261120

DOCA-PHARMA

ActivePrivate limited company1013.386.219Edgar Tinelstraat 11, 9112 Sint-Niklaas
Veterinary services (NACE 75000) · founded in 2024 · 1 employee on 31-12-2025 · accounts in the micro format

Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 24-07-2026; the Belgian Official Gazette, latest deed of 12-09-2024.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 1,973 micro companies in the veterinary activities sector (NACE 75) is below 0.1%.
Gross margin
-€27,380
-€18,752 in 2024, a financial year of 3 months
Net result
-€64,546
-€20,208 in 2024, a financial year of 3 months
Equity
-€79,753
-€15,208 in 2024
Cash
€1,237
▼ 96.8% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, DOCA-PHARMA made a loss of €64,546.Annual accounts 2025 page 2
  2. Equity is negative: -€79,753 on 31-12-2025.Annual accounts 2025 page 2
  3. Cash fell from €38,344 to €1,237. Debts due within one year rose from €4,490 to €62,137.Annual accounts 2024 and 2025 page 2
  4. Of the €152,137 of debt, €90,000 runs for more than a year.Annual accounts 2025, notes page 2
  5. The 2025 accounts reached the National Bank 7 days before the end of the term.National Bank, filing of 24-07-2026 page 4

Representation

The signing rule is in the founding deed of 12-09-2024.

Articles of association, Belgian Official Gazette of 12-09-2024, deed 24427889

Ownership

The accounts in the micro format list no shareholders. founded DOCA-PHARMA by deed of 12-09-2024. There is one other shareholder.

Deed of 12-09-2024

DOCA-PHARMA · 1013.386.219 · credit report of 20-11-2026Page 1 of 5
DOCA-PHARMA1013.386.219 · report of 20-11-2026

Financial situation

Annual accounts 2024 to 2025, as filed with the National Bank

Gross margin and net resultin euro

2024-18,7522025-27,3802024-20,2082025-64,546
gross marginnet result

Equity and debtsin euro

20242025-79,753152,137
equitydebts

Cashin euro

202438,34420251,237
on the balance sheet date
Financial year20243 months2025Trend
Results
Gross margin-€18,752-€27,380
Operating result-€20,186-€63,874
Net result-€20,208-€64,546
Balance sheet at the closing date
Equity-€15,208-€79,753
Debts€104,490€152,137
Debts due after more than one year€100,000€90,000
Debts due within one year€4,490€62,137
Cash€38,344€1,237
Balance sheet total€89,282€72,384
Operations
Employees in full-time equivalents-1.0
Ratios
Solvency-17.0%-110.2%
Liquidity9.790.47

Source: Annual accounts 2025, micro format, filed on 24-07-2026 (2026-00326447); Annual accounts 2024, micro format, filed on 14-07-2025 (2025-00264005).

Debts rose by €47,647 in 2025, of which €884 to suppliers.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

DOCA-PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from -€18,752 to -€27,380.

The financial year to 31-12-2024 ran for 3 months.

DOCA-PHARMA · 1013.386.219 · credit report of 20-11-2026Page 2 of 5
DOCA-PHARMA1013.386.219 · report of 20-11-2026

Board, signature and ownership

Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the founding deed of 12-09-2024.

Articles of association, Belgian Official Gazette of 12-09-2024, deed 24427889

Board

Director (not named in the articles)appointed by deed of 12-09-2024
term without a fixed enddeed of 12-09-2024
Director (not named in the articles)appointed by deed of 12-09-2024
term without a fixed enddeed of 12-09-2024

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. founded DOCA-PHARMA by deed of 12-09-2024. founded DOCA-PHARMA by deed of 12-09-2024.

Deed of 12-09-2024

DOCA-PHARMA · 1013.386.219 · credit report of 20-11-2026Page 3 of 5
DOCA-PHARMA1013.386.219 · report of 20-11-2026

Events and comparison

Every event since the founding, newest first

Annual accounts 2025 filed, 7 days before the deadline.

NBB filing

Annual accounts 2024 filed, 17 days before the deadline.

NBB filing

Incorporation. Founding capital of €5,000, 100 shares. Founded by and . (director) and (director) appointed. Published on 12-09-2024.

Gazette, deed 24427889

First establishment. Edgar Tinelstraat 11, Sint-Niklaas.

Comparable companies, two years later

In July 2024, 7,656 companies had the same profile as DOCA-PHARMA has now: micro, 2 to 5 years old, negative equity and a loss of 10% of the balance sheet or more. Two years later 84.7% were still trading, 6.5% had stopped another way and 8.8% had gone bankrupt.

still trading 84.7% stopped another way 6.5% bankrupt 8.8%

The return on assets of DOCA-PHARMA, -89.2%, is lower than at 95% of the 1,634 companies filing micro accounts in veterinary activities (NACE 75) in 2025.

Other findings

Peppol

Reachable for e-invoices, under 0208:1013386219.

Sanctions lists

Staff

1 employee on 31-12-2025, 0.6 full-time equivalents on average over the year.

DOCA-PHARMA · 1013.386.219 · credit report of 20-11-2026Page 4 of 5
DOCA-PHARMA1013.386.219 · report of 20-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units20-11-2026KBO 1013.386.219
National Bank of BelgiumAnnual accounts 2025, micro format24-07-20262026-00326447
National Bank of BelgiumAnnual accounts 2024, micro format14-07-20252025-00264005
Belgian Official GazetteFounding deed with the articles of association12-09-2024deed 24427889
Peppol DirectoryRegistration for e-invoices0208:1013386219
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies19-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

DOCA-PHARMA · 1013.386.219 · credit report of 20-11-2026Page 5 of 5